Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery

Digestive Diseases

Volumn 17, Issue 2, 1999, Pages 90-99

  Sanger, Gareth J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT4; 5 HT (serotonin); 5 HT3; Cholecystokinin; Corticotropin releasing factor; Fedotozine; Hyperreactivity; Hypersensitivity; Irritable bowel syndrome; N Methyl D aspartate; Somatostatin; Visceral perception

Indexed keywords

ALOSETRON; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CHOLECYSTOKININ; CISAPRIDE; CORTICOTROPIN RELEASING FACTOR; DELTA OPIATE RECEPTOR; FEDOTOZINE; HISTAMINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ; NEUROPEPTIDE RECEPTOR; OCTREOTIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; TRICYCLIC ANTIDEPRESSANT AGENT;

CENTRAL NERVOUS SYSTEM; DRUG INDUSTRY; FEMALE; HUMAN; HYPERSENSITIVITY; INTESTINE INNERVATION; IRRITABLE COLON; MALE; MOTOR SYSTEM; PRIORITY JOURNAL; REVIEW; SENSORY NERVE;

ABDOMINAL PAIN; AFFERENT PATHWAYS; ANIMALS; CISAPRIDE; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; DIARRHEA; HUMANS; INTESTINES; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SPINAL NERVES;

EID: 0032863410     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016910     Document Type: Review

References (105)

1. Farthing MJG: Irritable bowel, irritable body, or irritable brain? BMJ 1995;310:171-175.
2. Mayer EA, Munakata J, Mertz H, Lembo T, Bernstein CN: Visceral hyperalgesia and irritable bowel syndrome: in Gebhart GF (ed): Visceral Pain. Progress in Pain Research and Management. Seattle, IASP Press, 1995, vol 5, pp 429-468.
3. Kellow JE, Eckersley GM, Jones MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991;101:1621-1627.
4. Bueno L, Fioramonti J, Delvaux M, Frexinos J: Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations. Gastroenterology 1997;112:1714-1743.
5. Mayer EA: The sensitive and reactive gut. Eur J Gastroenterol Hepatol 1994;6:470-477.
6. Collins SM, McHugh K, Jacobson K, Khan I, Riddell R, Murase K, Weingarten HP: Previous inflammation alters the response of the rat colon to stress. Gastroenterology 1996;111:1509-1515.
7. Stum R, Croiset G, Akkermans LMA, Wiegant VM: Sensitization of the colonic response to novel stress after previous stressful experience. Am J Physiol 1996;271:R1270-R1273.
8. Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients. BMJ 1997;314:779-782.
9. Morrisyates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G: Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-1317.
10. Chang L, Saba L, Silverman DHS, Matin K, Mandelkern MA, Mayer EA: Differences in perception and brain activation in response to visceral stimuli in IBS patient and non-patient twins. Gastroenterology 1997;112(suppl 4): A709.
11. Harraf F, Schmulson M, Saba L, Niazi N, Fass R, Munakata J, Diehl D, Mertz H, Naliboff B, Mayer EA: Subtypes of constipation-predominant irritable bowel syndrome based on rectal perception. Gut 1998;43:388-394.
12. Connell AM, Jones FA, Rowlands EN: Motility of the pelvic colon. Part IV. Abdominal pain associated with colonic hypermotility after meals. Gut 1965;6:105-112.
13. Daly J, Bergin AJ, Donnelly TC, Read NW: Postprandial patterns of rectosigmoid contractions in patients with IBS and normals. Gastroenterology 1993;104:A494.
14. Maxton DG, Whorwell PJ: Abdominal distension in irritable bowel syndrome: The patient's perception. Eur J Gastroenterol Hepatol 1992; 4:241-243.
15. Hu WHC, Talley NJ: Visceral perception in functional gastro-intestinal disorders: Disease marker or epiphenomenon? Dig Dis 1996;14: 276-288.
16. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
17. Lembo T, Munakata J, Mertz H, Niazi N, Kodner A, Nikas V, Mayer EA: Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994;107:1686-1696.
18. Accarino AM, Azpiroz F, Malegelada J-R: Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995;108:636-643.
19. Malcolm A, Phillips SF, Camilleri M, Hanson RB: Pharmacological modulation of rectal tone alters perception of distension in humans. Am J Gastroenterol 1997;92:2073-2079.
20. Kolhekar R, Gebhart GF: NMDA and quisqualate modulation of visceral nociception in the rat. Brain Res 1994;651:215-226.
21. Ness TJ, Metcalf AM, Gebhart GF: A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus. Pain 1990;43:377-386.
22. Plourde V, Lembo T, Shui Z, Parker J, Mertz H, Tache Y, Sytnik B, Mayer EA: Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265:G742-G745.
23. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, Chang L, Silverman DHS, Mayer EA: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997;112: 55-63.
24. Cook AJ, Woolfe CJ, Wall PD, McMahon SB: Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature 1987;325:151-153.
25. Silverman DHS, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA: Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112:64-72.
26. Mayer EA: Gut feelings: What turns them on? Gastroenterology 1995;108:927-940.
27. Read NW: New directions in drug treatment of the irritable bowel syndrome: in Mayer EA, Raybould HE (eds): Basic and Clinical Aspects of Chronic Abdominal Pain. Amsterdam, Elsevier, 1993, pp 323-334.
28. Western AP, Biddle WL, Bhatia PS, Miner PB: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993;38:1590-1595.
29. Kyosola K, Pettila O, Salaspuro M: Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterology 1977;12:363-367.
30. Stead RH, Kosecka-Janiszewska U, Oestreicher AB, Dixon MF, Bienenstock J: Remodelling of B-50 (GAP-43)-and NSE-immunoreactive mucosal nerves in the intestines of rats infected with Nippostronglylus brasilienis. J Neurosci 1991;11: 3809-3821.
31. Saffrey MJ, Burnstock G: Growth factors and the development and plasticity of the enteric nervous system. J Auton Nerv Syst 1994;49: 183-196.
32. Fargeas MJ, Fioramonto J, Bueno L: The role of monoaminergic systems in central IL-1beta-induced changes in intestinal motility. Neurogastroenterol Motil 1994;6:189-191.
33. IP receptors on sensory CGRP neurons. Am J Physiol 1996;270:G778-G782.
34. Pettersson G: The neuronal control of the serotonin content in mammalian enterochromaffin cells. Acta Physiol Scand Suppl 1979;470:1-30.
35. Sanger GJ: 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996;8:319-331.
36. IA receptor agonist action in rats. Jpn J Pharmacol 1998; 77:211-217.
37. Mathias JR, Clench MH, Abell TL, Koch KL, Lehman G, Robinson M, Rothstein R, Snape WJ: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease. A double-bling, placebo-controlled, randomized study. Dig Dis Sci 1998;43:1347-1355.
38. Su X, Gebhart GF: Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent libers innervating the rat colon. Pain 1998;76:105-114.
39. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL: Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998;38:G460-G466.
40. Gorard DA, Libby GW, Farthing MJ: Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-166.
41. Julia V, Morteau O, Bueno L: Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology 1994;107:94-102.
42. 2 receptors. Eur J Pharmacol 1997;337:279-282.
43. McLean PG, Garciavillar R, Fioramonti J, Bueno L: Effects of tachykinin receptor antagonists on the rat jejunal distension pain response. Eur J Pharmacol 1998;345:247-252.
44. Ikeda K, Miyata K, Kubota H, Yamada T, Tomioka K: RP67580, a neurokinin 1 receptor antagonist, decreased restraint stress-induced defecation in rat. Neurosci Lett 1995;198:103-106.
45. Maggi CA, Patacchini R, Bartho L, Holzer P, Santiciloi P: Tachykinin NK, and NK receptor antagonists and atropine-resistant ascending excitatory reflex to the circular muscle of the guinea-pig ileum. Br J Pharmacol 1994;112: 161-168.
46. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT: Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study. Cephalagia 1997;17:785-790.
47. Schwartz JP: Neurotransmitters as neurotrophic factors: A new set of functions. Int Rev Neurobiol 1991;34:1-23.
48. Hockfelt T, Zhang X, Wiesenfeld-Hallin Z: Messenger plasticity in primary sensory neurons following axotomy and its functional consequences. Trends Neurosci 1994;17:22-30.
49. Allescher HD, Ahmad S, Classen M, Daniel EE: Interaction of trimebutine and Jo-1196 (fedotozine) with opioid receptors in the canine ileum. J Pharmacol Exp Ther 1991;257:836-842.
50. Langlois A, Diop L, Friese N, Pascaud X, Junien J-L, Dahl SG, Riviere PJM: Fedotozine blocks hypersensitive visceral pain in conscious rats: Action at peripheral K-opioid receptors. Eur J Pharmacol 1997;324:211-217.
51. Lacheze C, Coelho A-M, Fioramonti J, Bueno L: Influence of trimebutine on inflammation-and stress-induced hyperalgesia to rectal distension in rats. J Pharm Pharmacol 1998;50:921-928.
52. Delvaux M, Louvel D, Scherrer B, Fraitag B, Frexinos J: The k-agonist fedotozine increases thresholds of first sensation and pain perception to colonic distension in patients with irritable bowel syndrome. Gastroenterology 1995;108: A590.
53. Dapoigny M, Abitbol J-L, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995;40:2244-2248.
54. Hasler W, Soudah H, Owyang A: Somatostatin analogue inhibits afferent response to rectal distension in diarrhoea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268:1206-1211.
55. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-1178.
56. O'Donnell LJD, Watson AJM, Cameron D, Farthing MJG: Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in irritable bowel syndrome. Aliment Pharmacol Ther 1990;4:177-182.
57. Nakamura T, Kudoh K, Takebe K, Imamura K-I, Terada A, Kikuchi H, Yamada N, Arai Y, Tando Y, Machida K, Ishii M: Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994;33:593-596.
58. Foster JM, Houghton LA, Whorwell PJ: Alosetron slows colonic transit in patients with irritable bowel syndrome (IBS). Gastroenterology 1997;112:A732.
59. 3 antagonism (ondansetron). Digestion 1996;57:478-483.
60. Northcutt AR, Camilleri M, Mayer EA, Drossman DA, Dukes GE, Ehsanullah RSB, Hamm ER, Harding JP, Heath AT, Jacques E, Wolfe S, Kong S, MeSorley D, Mangel AW: Alosetron, a 5-HT3 receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology 1998;114:G3336.
61. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR: Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome - A pilot study. Mayo Clin Proc 1992; 67:732-738.
62. Schutz K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E: Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:387-394.
63. Noor N, Small PK, Loudon MA, Hau C, Campbell FC: Effects of cisapride on symptoms and postcibal small bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998;33:605-611.
64. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K: Effect of a novel prokinetic drug R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-516.
65. 4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997;62:546-555.
66. Briejer MR, Akkermans LMA, Schuurkes JAJ: Gastrointestinal prokinetic benzamides: The pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631-651.
67. Sjolund K, Ekman R, Lindgren S, Rehfeld JF: Disturbed motilin and cholecystokinin release in the irritable bowel syndrome. Scand J Gastroenterol 1996;31:1110-1114.
68. Barrow L, Blackshaw PE, Wilson CG, Rovati L, Spiller RC: Selective slowing of proximal colon transit in irritable bowel syndrome by the cholecystokinin receptor antagonist, loxiglumide. Eur J Gastroenterol Hepatol 1994;6:381-387.
69. Niederau C, Faber S, Karaus M: Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome. Gastroenterology 1992;102:1889-1898.
70. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC: A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995; 15:428-434.
71. Stefanini GF, Prati E, Abini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G: Oral disodium cromoglycate treatment on irritable bowel syndrome. An open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992;87:55-57.
72. Gue M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L: Stress-induced visceral hypersensitivity to rectal distension in rats: Role of CRF and mast cells. Neurogastroenterol Motil 1997;9:271-279.
73. Castagliuolo I, Wershil BK, Karalis K, Pasha A, Nikulasson ST, Pothoulakis C: Colonic mucin release in response to immobilization stress is mast cell-dependent. Am J Physiol 1998;37: G1094-G1100.
74. Coelho A-M, Fioramonti J, Bueno L: Mast cell degranulation induces delayed rectal allodynia in rats. Role of histamine and 5-HT. Dig Dis Sci 1998;43:727-737.
75. Verbeuren TJ: Synthesis, storage, release and metabolism of 5-hydroxytryptamine in peripheral tissues; in Fozard JR (ed): The Peripheral Actions of 5-Hydroxytryptamine. Oxford, Oxford University Press, 1989, pp 1-25.
76. Gue M, Junien JL, Bueno L: Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology 1991;100:964-970.
77. Lechner SM, Curtis AL, Brons R, Valentine RJ: Locus coeruleus activation by colon distension: Role of corticotropin-releasing factor and excitatory amino acids. Brain Res 1997;756:114-124.
78. Kawahito Y, Sano H, Kawata M, Yuri K, Mukai S, Yamamura Y, Kato H, Chrousos GP, Wilder RL, Kundo M: Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon. Gastroenterology 1994;106:859-865.
79. Pothoulakis C, Castagliuolo I, Leeman SE: Neuroimmune mechanisms of intestinal responses to stress Role of corticotropin-releasing factor and neurotensin. Ann NY Acad Sci 1998;840:635-648.
80. Lembo T, Plourde V, Shui Z, Fullerton S, Mertz H, Tache Y, Sytnik B, Munakata J, Mayer E: Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil 1996;8:9-18.
81. Fukudo S, Nomtira T, Hongo M: Impact of corticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42:845-849.
82. 3 receptors on colonic transit in rats. Obes Res 1995;3(suppl 5):801-810.
83. 3 receptor in CRH-induced defecation in rats. Am J Physiol 1998;37:G827-G831.
84. Burks TF, Long JP: Catecholamine-induced release of 5-hydroxytryptamine from perfused vasculature of isolated dog intestine. J Pharmacol Sci 1966;55:1383-1386.
85. Bearcroft CP, Perrett D, Farthing MJG: Post-prandial plasma 5-hydroxytryptamine in diarrhoea-predominant irritable bowel syndrome: A pilot study. Gut 1998;42:42-46.
86. Sanger GJ, Wardle KA: 5-Hydroxytryptamine and cholinergic function in the gastrointestinal tract; in Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds): Serotonin: From Cell Biology to Pharmacology and Therapeutics. Amsterdam, Kluwer, 1990, pp 251-255.
87. 4 receptor antagonists and their potential therapeutic utility. Drugs Future 1994;19:1109-1121.
88. 4 receptor activation. Eur J Pharmacol 1994; 271:741-747.
89. 4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models. Neurogastroenterol Motil 1998;10:271-279.
90. Tonini M, Galligan JJ, North RA: Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea-pig ileum. Gastroenterology 1989;96:1257-1264.
91. 4 receptors in ascending and descending reflexes to the circular muscle of guinea-pig small intestine. Br J Pharmacol 1994;112:1095-1100.
92. 4 receptor activation. Br J Pharmacol 1991; 102:563-564.
93. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD: Localisation and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996;16:2352-2364.
94. 4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum. Br J Pharmacol 1993;110:1572-1578.
95. 4 receptor agonists initiate the peristaltic reflex in human, rat and guinea-pig intestine. Gastroenterology 1998;115:370-380.
96. 4 receptors in 5-hydroxytryptophan-induced diarrhoea in mice. J Pharmacol Exp Ther 1994;271:741-747.
97. Moore BA, Sharkey KA, Mantle M: Rule of 5-HT in cholera toxin-induced mucin secretion in the rat small intestine. Am J Physiol 1996; 270:G1001-G1009.
98. 4 receptor. Am J Physiol 1994;267:G357-G363.
99. 4 receptor antagonist. Br J Pharmacol 1995;115:1087-1095.
100. 4 antagonists of stress-induced colonic dysfunction and visceral pain in the rat. Gastroenterology 1996; 110:A735.
101. Doak GJ, Sawynok J: Formalin-induced nociceptive behavior and edema: Involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. Neuroscience 1997;80:939-949.
102. 3 receptors. Brain Res 1998;788:20-24.
103. 4 receptors couple positively to tetrodotoxin-insensitive sodium channels in a subpopulation of capsaicin-sensitive rat sensory neurons. J Neurosci 1997;17:7181-7189.
104. Lincoln J, Crowe R, Kamm MA, Burnstock G, Lennard-Jones JE: Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon in severe idiopathic constipation. Gastroenterology 1990;98:1219-1225.
105. 4 antagonism in irritable bowel syndrome (IBS): Effect of SB-207266-A on rectal sensitivity and small bowel transit. Gut 1997;41(suppl 3):A26.